Breaking News on Contract Research, Manufacturing & Clinical Trials

Hot Topics > Consolidation

Big Pharma's 'intellectual arrogance' stunts CMO partnerships, says GPCM Chair

22-Jul-2014 - Efficient relationships with contract manufacturers are being held back by Big Pharma’s ‘intellectual arrogance’ and ill-defined operational teams, according to an ex-Director at GlaxoSmithKline.

Chiltern taps oncology expertise with Ockham acquisition

16-Jul-2014 - UK-based CRO Chiltern has agreed to acquire Ockham, a North Carolina-based full-service CRO, and the combined company will now compete with mid-sized CROs. Financial terms of the acquisition were not...

CROs see high jobs growth as bio industry remains relatively flat, report finds

15-Jul-2014 - While the overall bioscience industry has seen 7.4% jobs growth between 2001 and 2012, the sector encompassing CROs and other research, testing and medical labs has grown by more than...

Clinical Cymru: Simbec Research buys Orion Clinical Services for £12.5m

24-Jun-2014 - Simbec Research has bought Orion Clinical Services in the latest deal backed by the Welsh Government’s £100m life sciences investment fund.

Dispatches from the GPCM Conference, London, UK

For big pharma, ten is the magic number of CMOs says ex-GSK Director

18-Jun-2014 - Big pharma is moving towards strategic partnerships with CMOs, according to speakers at the Global Pharmaceutical Contract Manufacturing (GPCM) Conference, with the ideal number of partners being ten.

Business as usual for CROs as megamerger optimism subsides

11-Jun-2014 - When it comes to pharma acquisitions size does matter, according to analyst Ross Muken who says the momentary lapse in megamergers means business as usual for CROs.

Hikma eyes Ben Venue's assets as part of $300m Bedford Labs acquistion

29-May-2014 - Hikma Pharmaceuticals says it is evaluating Ben Venue’s manufacturing facility as an option in its $300m (€220m) acquisition of Bedford Laboratories.

Exclusive Interview

Lilly focuses in-house as manufacturing becomes more complex

27-May-2014 - Eli Lilly is maintaining greater in-house control as manufacturing processes become more complex, whilst MSD is leveraging external over-capacity to fulfil its needs, the firms told during a recent...

Huntingdon buys Harlan to form 3rd largest preclinical CRO

07-May-2014 - Huntingdon Life Sciences has acquired contract research and animal models firm Harlan Laboratories, making it the third largest preclinical research organisation, according to the company.

Quintiles, Covance upbeat on further pharma consolidation

06-May-2014 - Quintiles and Covance have re-iterated previous CROs’ upbeat stances on the prospect for further pharma M&A as they both reported revenue growth for the quarter.

Icon and Parexel: Pfizer-AZ merger will bring more business for CROs

05-May-2014 - A mega-merger between Pfizer and AstraZeneca would bring increased business to CROs say Icon and Parexel, if past experiences are to go by.

Hot topic

PE's unclear role in CRO industry leaves sponsors 'uncomfortable,' says expert

28-Apr-2014 - The relationship between private equity (PE) management and that of its CRO is “pivotal,” according to the Chairman of one pharma group, as PE’s undefined objectives and exit strategies are...

Biogen Idec selects Quintiles in 5-year strategic partnership

24-Apr-2014 - Biogen Idec’s five-year deal is the latest example of biopharma embracing the strategic partnership model, but the choice of Quintiles is somewhat of a surprise, according to ISI analyst Ross...

CROs to profit from large slice of $91bn biotech pie, say analysts

10-Apr-2014 - Much of the $91bn (€66bn) raised in biotech capital over the last twelve months will end up in the hands of the CRO industry, according to a survey from analyst...

Pernix leaves CMO business behind, sells off last manufacturing facility in Texas

03-Apr-2014 - Pernix Therapeutics will no longer be a CMO as it has signed a definitive agreement to divest its Houston, Texas-based manufacturing operations to Woodfield Pharmaceutical to cut costs.

Completed Galapagos deal to boost 2014 sales by $70m for Charles River

02-Apr-2014 - Argenta and BioFocus will add approximately $70m (€51m) to Charles River Laboratories’ 2014 revenues, the firm and an analyst say.

Dispatches from interphex

Consolidation prevalent in industry, says third largest CMO

26-Mar-2014 - Aenova says the acquisition of Haupt Pharma and Patheon’s merger with DSM are evidence of consolidation in the CMO industry, as it looks to further increase its global footprint.

Evotec buys academic asset management specialist

24-Mar-2014 - Evotec AG has bought an asset management company that specialises in bringing academic discovery and development innovations to the attention of pharma and biopharma sponsors.


Patheon and DSM crossover limited, more growth targeted says DPx

20-Mar-2014 - Patheon and DSM’s Pharma Products merger is “highly complementary” with crossover limited to North American oral solid manufacturing growth, says DPx as it targets further growth opportunities.

Patheon and DSM fully complementary for biologics post-merger, says DPx Exec

14-Mar-2014 - Patheon brings fill/finish capabilities to DSM’s biomanufacturing services, President of Biopharma at the recently merged company DPx told in an exclusive interview.

Exclusive interview

CMO future? Consolidation and strategic alliances, says Patheon/DSM Exec

13-Mar-2014 - In an exclusive interview, Patheon Executive Mike Lehmann talks DSM integration, further growth and how consolidation amongst CMOs may be driving strategic alliances with pharma.

breaking news - update 2

CRL to buy Argenta and Biofocus from Galapagos for €134m

13-Mar-2014 - Preclinical CRO Charles River Labs has announced plans to buy discovery services firms Argenta and BioFocus from Galapagos NV.

Exclusive interview

INC Research expands into Middle East with MEK acquisition

10-Mar-2014 - In a sign of further consolidation, CRO INC Research has acquired CRO MEK Consulting and will absorb its more than 40 employees based in the Middle East and north Africa.

DSM's pharma biz reports slight growth before Patheon merger

26-Feb-2014 - DSM has reported modest growth in its pharma business as a shareholders advisory firm comes out in favour of the upcoming merger with Patheon.

Private equity firm buys Medpace for $915m, citing growth opportunities

24-Feb-2014 - CRO consolidation has left market opportunities for providers who serve mid-size pharma, UK-based private equity firm Cinven says as it acquires Medpace.

Key Industry Events


Access all events listing

Our events, Shows & Conferences...